AMPIVIEW® RNA probes
Enabling Your Projects 
GMP Services
Bulk Solutions
Research Travel Grant
Have You Published Using an Enzo Product?
Shipping: Available products typically ship within 24/48h, via priority shipping.
Do you need support? Contact Customer Service or Technical Support.
Online Account
Access or Create Your Account
This antibody is covered by our Worry-Free Guarantee.
Figure 2: Western blot using PAb to PDE5A (Prod. No. ALX-210-099) at 1:1’000 dilution.Lane 1) 200µg of 15’000 x g supernatant of lysate from mouse brain. Lane 2) Mouse heart. Lane 3) Mouse lung. Lane 4) Mouse liver. Lane 5) 5ng of purified bovine PDE5.”””,PDE5A polyclonal antibody Western blot,PDE5A polyclonal antibody Western blot,yes
ALX-210-099,210-099_1.gif,http://static.enzolifesciences.com/fileadmin/files/image/210-099_1.gif,Figure 1: Western blot using PAb to PDE5A (Prod. No. ALX-210-099) at 1:1’000 dilution.Lane 1) 100µg of PDE5A-deficient SKN-BE2 neuroblastoma lysate. Lane 2) 100µg lysate mixed with 5ng of purified recombinant bovine PDE5A (Prod. No. ALX-201-257). Lane 3) 3ng of partially purified recombinant bovine PDE5A. Signal was developed for 5 sec. using ECL-Plus reagent (Amersham).”””””
Figure 1: Western blot using PAb to PDE5A (Prod. No. ALX-210-099) at 1:1’000 dilution.Lane 1) 100µg of PDE5A-deficient SKN-BE2 neuroblastoma lysate. Lane 2) 100µg lysate mixed with 5ng of purified recombinant bovine PDE5A (Prod. No.ALX-201-257). Lane 3) 3ng of partially purified recombinant bovine PDE5A. Signal was developed for 5 sec. using ECL-Plus reagent (Amersham).
The effect of diabetes mellitus and cinaciguat on myocardial NO-sGC-cGMP-PKG signalling. a Relative protein expression and representative immunoblot bands of endothelial nitric oxide synthase (eNOS), soluble guanylate cyclase β1 (sGC β1), phosphodiesterase 5A (PDE-5) (P value of diabetes × treatment interaction in the two-factorial ANOVA, Pinteraction = 0.024), protein kinase G (PKG), vasodilator-stimulated phosphoprotein (VASP) to phospho-VASP (p-VASP) ratio (Pinteraction = 0.003). b Relative gene expression of eNOS (Pinteraction = 0.039). Groups: vehicle-treated control (Co), cinaciguat-treated control (CoCin), vehicle-treated diabetic (DiabCo) and cinaciguat-treated diabetic (DiabCin). Bar graphs represent mean ± SEM of 5–6 experiments per group.*P < 0.05 vs. Co, †P < 0.05 vs. DiabCo (Tukey HSD test)
Image collected and cropped by CiteAb under a CC-BY license from the following publication: The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus. Cardiovasc Diabetol (2015)
| Regulatory Status |
RUO – Research Use Only |
|---|